Skip to content

Released Aug 6, 2025, after the close

10-Q filed Aug 6, 2025, 37 days after period end · 0001628280-25-038422

Q2 2025 · 10-Q
Revenue$45.60M−2.2% vs Q2 2024+10.0% vs Q1 2025
Net Income-$5.58MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.04N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$23,867,000−6.2%
Operating Income-$10,624,000N/M
Operating Cash Flowderived$108,000−98.3%
Free Cash Flowderived-$1,469,000N/M
Margins · derived
Gross margin52.3%−2.2 pt vs Q2 2024
Operating margin-23.3%−5.0 pt vs Q2 2024
Net margin-12.2%+10.1 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$45.60M$46.62M$49.69M$40.16M
Net Income-$5.58M-$10.43M-$4.39M-$702.00K
EPS Diluted-$0.04-$0.08-$0.03$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR